文献速递淋巴瘤

博纳吐单抗联合来那度胺治疗复发/难治性B细胞淋巴瘤的1期研究:毒性、疗效及相关性分析

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
PubMed 文献 · Blood Adv · 2026-01-01

该1期研究探索博纳吐单抗联合来那度胺治疗复发/难治性B细胞非霍奇金淋巴瘤,35例入组、34例开始治疗,确定最大耐受剂量/2期推荐剂量为来那度胺20mg第1-21天及第29-49天联合博纳吐单抗9/28/112μg/d持续静脉输注。最常见≥2级不良事件为神经毒性(11/34,32%),2期推荐剂量下1例剂量限制性毒性;完成诱导者总缓解率80%(95%CI 56-94),完全缓解率70%,8/34例(24%)缓解持续>2年。

要点

  • 确定最大耐受剂量/2期推荐剂量为来那度胺20mg联合博纳吐单抗9/28/112μg/d持续静脉输注方案。
  • 最常见≥2级不良事件为神经毒性,34例中11例(32%),2期推荐剂量下16例中4例(25%)。
  • 完成诱导者总缓解率80%(95%CI 56-94),完全缓解率70%,8/34例(24%)缓解持续>2年。

核心结论

  • 博纳吐单抗联合来那度胺在经重度治疗的复发/难治性B细胞非霍奇金淋巴瘤中显示出令人鼓舞的活性(NCI方案号9924)。

研究设计与样本

  • 1期试验,探索博纳吐单抗联合来那度胺治疗复发/难治性B细胞非霍奇金淋巴瘤,共3个剂量水平、2种给药方案。
  • 主要终点为不良事件和确定最大耐受剂量/2期推荐剂量;35例入组,34例开始治疗,既往中位治疗方案数为3(范围2-8)。

主要发现

  • 前2个剂量水平未出现剂量限制性毒性;剂量水平3(来那度胺20mg每日第1-21天及第29-49天,联合博纳吐单抗9μg/d持续静脉输注第1-7天、28μg/d第8-14天、112μg/d第15-56天,56天诱导周期)确定为最大耐受剂量/2期推荐剂量。
  • 最常见≥2级不良事件为神经毒性,34例中11例(32%),2期推荐剂量下16例中4例(25%);2期推荐剂量下发生1例剂量限制性毒性(2级震颤和找词困难)。
  • 完成诱导的患者总缓解率为80%(95%置信区间56-94),完全缓解率70%,34例中8例(24%)缓解持续>2年。
  • 基线外周血GranB+ CD56bright CD16dim CD11b+自然杀伤细胞和记忆调节性T细胞可预测缓解;同时给予来那度胺似乎减少博纳吐单抗介导的T细胞耗竭。

关键数值与推荐

  • 最大耐受剂量/2期推荐剂量:来那度胺20mg每日第1-21天及第29-49天,联合博纳吐单抗9μg/d持续静脉输注第1-7天、28μg/d第8-14天、112μg/d第15-56天(56天诱导周期)。
  • 完成诱导者总缓解率80%(95%置信区间56-94),完全缓解率70%。
  • 34例中8例(24%)缓解持续>2年;2期推荐剂量下16例中4例(25%)发生≥2级神经毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite a recent increase in therapeutic options, patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) eventually require novel therapies. We conducted a phase 1 trial of blinatumomab and lenalidomide in R/R B-NHL. Three dose levels representing 2 schedules were explored. The primary end points were adverse events (AEs) and determining the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D). Thirty-five patients were enrolled, and 34 patients initiated treatment with a median number of prior regimens of 3 (range, 2-8). There were no dose-limiting toxicities (DLTs) in the first 2 dose levels. Dose level 3, 20 mg of lenalidomide daily on days 1 to 21 and days 29 to 49 of a 56-day induction cycle plus blinatumomab 9 μg/d continuous IV infusion (CIVI) on days 1 to 7, 28 μg/d CIVI on days 8 to 14, and 112 μg/d CIVI on days 15 to 56 was determined to be the MTD/RP2D. The most common grade ≥2 AE was neurotoxicity in 11 of 34 patients (32%), with 4 of 16 patients (25%) at the RP2D. At the RP2D, there was 1 DLT, a patient with grade 2 tremor and word-finding difficulty. For all patients completing induction, the overall response rate was 80% (95% confidence interval, 56-94) with a complete response rate of 70%, and 8 of 34 patients (24%) had durable remissions lasting >2 years. GranB+ CD56bright CD16dim CD11b+ natural killer cells and memory regulatory T cells in the peripheral blood at baseline were predictive of response. Concomitant administration of lenalidomide appeared to reduce blinatumomab-mediated T-cell exhaustion. In conclusion, encouraging activity was seen with blinatumomab and lenalidomide in heavily pretreated R/R B-NHL (NCI Protocol no. 9924).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tuscano JM, Othman T, Frankel P, et al. A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis. Blood Adv. 2026. PMID: 41213001. doi:10.1182/bloodadvances.2025016845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。